Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)
Authors:
- Rayan KabirianRKRayan Kabirian
- Mathilde de Saint GhislainMGMathilde de Saint Ghislain
- Olivia Le SauxOSOlivia Le Saux
- Laurent MathiotLMLaurent Mathiot
- Jean-Sébastien FrenelJFJean-Sébastien Frenel
- Paule AugereauPAPaule Augereau
- Alexandra ForestierAFAlexandra Forestier
- Jean David FumetJFJean David Fumet
- Lauriane EberstLELauriane Eberst
- Stanislas QuesadaStanislas Quesada
- Elsa KalbacherEKElsa Kalbacher
- Céline LescureCLCéline Lescure
- 15 July 2026
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (9)
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialGynecologic Oncology, 2026
- The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancerCancer Medicine, 2024
- Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerAnnals of Oncology, 2024
- Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumoursAnnals of Medicine, 2023
- Dostarlimab for Primary Advanced or Recurrent Endometrial CancerNew England Journal of Medicine, 2023
- Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerNew England Journal of Medicine, 2023
- Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trialsCancer Treatment Reviews, 2022
- Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literatureCritical Reviews in Oncology/Hematology, 2022
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsEuropean Journal of Cancer, 2021
- Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapyEuropean Journal of Immunology, 2021